1. Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

2. Local Consolidative Therapy in Oligometastatic NSCLC: Background
Evidence from preclinical and retrospective studies suggest that some pts with metastatic NSCLC may have a less aggressive or “limited metastatic” phenotype and may benefit from more aggressive therapy; this is known as “oligometastatic disease”
The role of aggressive local therapy in this context remains controversial
Not yet addressed in randomized trials
Current multi-institutional phase II randomized trial evaluated efficacy of LCT for patients with oligometastatic NSCLC not progressing after first-line systemic therapy
LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

3. LCT in Oligometastatic NSCLC: Randomized Phase II Study Design
Stratified by nodal status (NO/N1 vs N2/N3), EGFR/EML4-ALK status (yes/no), CNS metastases (yes/no), number of metastases (1 vs 2/3), and response to FLST (SD vs PR/CR)
No Local Consolidative Therapy (n = 24)
Histologically confirmed stage IV NSCLC, no RECIST progression after FLST, ≤ 3 metastases after FLST
(n = 49)
Standard maintenance or observation†
Crossover allowed at PD
Consider LCT (surgery ± radiation)
FLST*
(N = 74)
PD/Toxicity
Local Consolidative Therapy (n = 25)
LCT
(surgery ±
radiation)
Standard
maintenance or
observation† PD
*≥ 4 cycles of platinum-doublet chemotherapy, or ≥ 3 mos of afatinib, erlotinib, or gefitinib in setting of EGFR mutation, or ≥ 3 mos of crizotinib if EML4-ALK fusion; pts could enroll before or during FLST, but randomization occurred after completion of FLST without progression. †Physician choice.
CNS, central nervous system; FLST, first-line systemic therapy; LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors.
Primary outcome: PFS
Time from randomization to PD or death if endpoint met, time from randomization to last imaging if no progression, and censored at time of crossover due to toxicity
Follow-up every 6-10 wks in Yr 1, then at physician’s discretion
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

4. LCT in Oligometastatic NSCLC: Pt Characteristics
Treatment arms well balanced with respect to age, race, sex, histology, and balanced prognostic factors
Treatment Regimens in LCT Arm, n (%)
Pts (N = 25)
Hypofractionated RT/SBRT
13 (52)
Combination CRT and hypofractionated RT
4 (16)
Combination surgery and RT
3 (12)
CRT alone
Surgery alone
1 (4)
Progressed prior to local treatment
CRT, chemoradiotherapy; LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer; RT, radiotherapy; SBRT, stereotactic body radiation therapy.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

5. LCT in Oligometastatic NSCLC: PFS and OS
Study closed by DSMC due to observed efficacy in the LCT arm after 49 patients randomized, at median follow-up of 18.7 months
Median PFS
No LCT : 3.9 mos (95% CI: )
LCT: 11.9 mos (95% CI: 5.4-NA; P = .005)
Other factors associated with improved PFS included number of metastases after FLST (1 vs 2 or 3; P = .043) and EGFR/ALK status (positive vs negative; P = .035)
PFS benefit remained after censoring pts with EGFR/ALK alterations (HR: 0.41; 95% CI: ; P = .022)
Median OS not reached in either arm, and data not mature
Deaths: 14 (6 in LCT arm; 8 in no-LCT arm)
DSMC, data and safety monitoring committee; FLST, first-line systemic therapy; LCT, local consolidative therapy; NA, not available; NSCLC, non-small-cell lung cancer
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

6. LCT in Oligometastatic NSCLC: Patterns of Failure
Progression in 30 pts (61%), most often in new lesions (n = 14) or distant metastases (n = 16); progression at combination of new and known sites also common (n = 9)
LCT arm had primarily distant and new lesion failures; no-LCT arm had more locoregional failures and combined new and known site failures
Trend toward significance in patterns of failure (P = .09)
Locoregional-only failures higher in no-LCT arm vs LCT arm (17% vs 4%)
Metastatic-only failures higher in LCT arm vs no-LCT arm (40% vs 25%)
Both locoregional/metastatic failures higher in no-LCT vs LCT arm (29% vs 8%)
Median TNSF: 11.9 mos in LCT arm vs 5.7 mos in no-LCT arm (P = .0497)
LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer; TNSF, time to new site failure.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

7. LCT in Oligometastatic NSCLC: Crossovers
3 crossovers prior to PD: fatigue, chemotherapy- related anemia, renal failure
17 pts had PD in no-LCT arm
11 crossed over and had LCT (6 hypofractionated RT/SBRT, 3 surgery only, 1 surgery/RT, 1 SBRT/chemoRT)
LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer; PD, progressive disease; RT, radiotherapy; SBRT, stereotactic body radiotherapy.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

8. LCT in Oligometastatic NSCLC: Toxicity
No substantial toxicity differences observed between arms
No-LCT arm: 3 pts crossed over due to toxicity
1 anemia, 1 fatigue, 1 renal insufficiency
1 discontinuation due to bilateral edema of the lower extremities
LCT arm
Grade 3 esophagitis: 2
1 anemia, 1 pneumothorax, 1 pain
LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

9. LCT in Oligometastatic NSCLC: Conclusions
LCT associated with improved PFS in pts with oligometastatic NSCLC and no progression after FLST
Limitations include small pt number, pt/treatment heterogeneity, and select group of pts represented
In exploratory analyses, LCT increased time to development of new lesions, suggesting that this strategy reduces metastatic spread
LCT toxicity profile acceptable and not substantially different from that of no-LCT arm
FLST, first-line systemic therapy; LCT, local consolidative therapy; NSCLC, non-small-cell lung cancer.
Slide credit: clinicaloptions.com
Gomez DR, et al. ASCO Abstract 9004.

10. Go Online for More CCO Coverage of ASCO 2016!
Short slideset summaries of all the key data
Additional CME-certified analyses with expert faculty commentary on all the key studies in:
Breast, genitourinary, and lung cancers
Hematologic malignancies
Immunotherapy
clinicaloptions.com/oncology